Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Cosciens Biopharma's Sloan Ratio for the quarter that ended in Mar. 2026 was 67.35%.
As of Mar. 2026, Cosciens Biopharma has a Sloan Ratio of 67.35%, indicating there is a warning stage of accrual build up.
Cosciens Biopharma (OTCPK:CSCID) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2026, Cosciens Biopharma has a Sloan Ratio of 67.35%, indicating there is a warning stage of accrual build up.
Cosciens Biopharma Sloan Ratio % Related Terms
Cosciens Biopharma Sloan Ratio % Historical Data
* Premium members only.
The historical data trend for Cosciens Biopharma's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSCID vs VRTX, REGN, ALNY: Sloan Ratio % Comparison
For the Biotechnology subindustry, Cosciens Biopharma's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosciens Biopharma Sloan Ratio % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Cosciens Biopharma's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Cosciens Biopharma's Sloan Ratio for the fiscal year that ended in Dec. 2025 is calculated as
Cosciens Biopharma's Net Income for the trailing twelve months (TTM) ended in Mar. 2026 was -2.701 (Jun. 2025 ) + -1.819 (Sep. 2025 ) + -2.183 (Dec. 2025 ) + 10.757 (Mar. 2026 ) = $4.05 Mil.
Cosciens Biopharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was -4.447 (Jun. 2025 ) + -0.676 (Sep. 2025 ) + -1.47 (Dec. 2025 ) + -2.177 (Mar. 2026 ) = $-8.77 Mil.
Cosciens Biopharma's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2026 was -0.048 (Jun. 2025 ) + 0.004 (Sep. 2025 ) + 0.201 (Dec. 2025 ) + -0.023 (Mar. 2026 ) = $0.13 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosciens Biopharma (CSCID) has a Sloan Ratio % of 67.35% as of Mar. 2026. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Cosciens Biopharma and its competitors.
Is Cosciens Biopharma's Sloan Ratio % too high?
Cosciens Biopharma's current Sloan Ratio % is 67.35%. Overall, Cosciens Biopharma has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cosciens Biopharma's Sloan Ratio % compare to VRTX and REGN?
Cosciens Biopharma's Sloan Ratio % of 67.35% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Biotechnology company?
A good Sloan Ratio % depends on the Biotechnology industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Cosciens Biopharma and its competitors. Cosciens Biopharma's current Sloan Ratio % is 67.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosciens Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cosciens Biopharma (CSCID) is currently considered Fairly Valued. The stock's GF Value™ is $6.57, compared to a current price of $7.00 — trading 6.5% above its estimated fair value. The current Sloan Ratio % is 67.35%. Cosciens Biopharma's overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Cosciens Biopharma (CSCID), the current Sloan Ratio % is 67.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosciens Biopharma (CSCID) Overvalued in 2026?
Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be overvalued.
The current stock price of $7.00 is trading 6.5% above its estimated GF Value™ of $6.57.
GuruFocus considers Cosciens Biopharma to be Fairly Valued.
Key valuation signals for CSCID:
Sloan Ratio %: 67.35%
GF Value™: $6.57 vs. price of $7.00 (6.5% above fair value)
No single metric tells the full story. See the CSCID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
61GF Score
Get the complete analysis for CSCID
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSCID has been successfully added to your 
